Drug Trial Radar · NCT01508936
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
Last checked: Nov 20, 2026Latest source record: Jun 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
511
Actual
Start
Feb 2012
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Jan 12, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to baseline blood eosinophil levels in patients with moderate to severe asthma, as assessed by the change from baseline to week 16 in forced expiratory volume in 1 second (FEV1).
Conditions
- Eosinophilic Asthma
Interventions
ReslizumabDrug
Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
PlaceboDrug
Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis SetTime frame: Baseline (Day 1), Week 16
Locations
66 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site 861
Birmingham, Alabama
Investigational Site 842
Homewood, Alabama
Investigational Site 887
Jasper, Alabama
Investigational Site 809
Tucson, Arizona
Investigational Site 892
Tucson, Arizona
Investigational Site 846
Little Rock, Arkansas
Investigational Site 828
Anaheim, California
Investigational Site 900
Fresno, California
Investigational Site 862
Huntington Beach, California
Investigational Site 852
Los Angeles, California
Investigational Site 909
Los Angeles, California
Investigational Site 864
Newport Beach, California
Investigational Site 812
Rancho Mirage, California
Investigational Site 808
Riverside, California
Investigational Site 804
Sacramento, California
Investigational Site 837
Centennial, Colorado
Investigational Site 851
Denver, Colorado
Investigational Site 832
Wheat Ridge, Colorado
Investigational Site 855
Jacksonville, Florida
Investigational Site 865
Miami, Florida
Investigational Site 881
Miami, Florida
Investigational Site 805
Albany, Georgia
Investigational Site 870
Stockbridge, Georgia
Investigational Site 816
Chicago, Illinois
Investigational Site 824
Shiloh, Illinois
Investigational Site 883
Evansville, Indiana
Investigational Site 878
Fort Wayne, Indiana
Investigational Site 820
Lenexa, Kansas
Investigational Site 873
Owensboro, Kentucky
Investigational Site 801
Lafayette, Louisiana
Investigational Site 877
Mandeville, Louisiana
Investigational Site 875
White Marsh, Maryland
Investigational Site 871
Fall River, Massachusetts
Investigational Site 834
North Dartmouth, Massachusetts
Investigational Site 889
Troy, Michigan
Investigational Site 838
Rolla, Missouri
Investigational Site 818
St Louis, Missouri
Investigational Site 841
St Louis, Missouri
Investigational Site 857
Albuquerque, New Mexico
Investigational Site 819
Newburgh, New York
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.